Bristol Myers Squibb Expands Direct-to-Patient Access With New Sotyktu Program

Author(s):

Key Takeaways

Bristol Myers Squibb's "BMS Patient Connect" platform offers Sotyktu at over 80% less than the list price, enhancing accessibility for psoriasis patients.
Eliquis, an anticoagulant, is available at a 40% discount, reducing healthcare costs and improving access for patients with atrial fibrillation and other conditions.
The direct-to-patient model aims to lower out-of-pocket costs, provide transparency, and support patients, potentially expanding to other BMS medicines in the future.

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, making the treatment for affordable and accessible for US patients.

Image Credit: Adobe Stock Images/PixelBiss.com

Bristol Myers Squibb is growing its direct-to-patient services, which involves offering US patients discounted prices for its Sotyktu (deucravacitinib) and Eliquis(apixaban) products.¹ For cash-pay patients that qualify, they can buy these meds straight from BMS, lowering their out-of-pocket costs in the process.

Sotyktu now available at over 80% less than list price

Beginning this January, Sotyktu—which is BMS’ tyrosine kinase 2 (TYK2) inhibitor that treats moderate-to-severe plaque psoriasis—will be sold via the company’s new “BMS Patient Connect” platform.

The new platform will offer Sotyktu at more than 80% less than the current list price.

“We are proud to now offer Sotyktu at a lower price via “BMS Patient Connect,” our new direct-to-patient platform designed to make our innovative medicines more accessible and affordable for patients living with serious conditions,” said Christopher Boerner, PhD, board chair and CEO of Bristol Myers Squibb. “We are taking a leading role in removing barriers, providing transparency and lowering out-of-pocket costs so patients in the United States can get the treatments they need—delivered directly to their door, wherever they are in the country.”

“BMS Patient Connect” offers shipping to all 50 states and Puerto Rico, alongside clear, upfront pricing, which creates a straightforward and convenient access option for patients. The program even offers patient support tools, while leaving the door open for other BMS medicines in the pipeline to also use this type of model down the road.

Eliquis program delivers savings and expanded access

This BMS news follows the momentum garnered by the company’s Bristol Myers Squibb-Pfizer Alliance program² for Eliquis—featuring a discounted rate of more than 40% less than the current list price—that launched Sept. 8.

Fast Facts

New platform: BMS Patient Connect launches January with Sotyktu access.
Discounts: Sotyktu available at 80%+ below list price
Nationwide access: Shipping available to all 50 states and Puerto Rico.

Making medicines more affordable and accessible

Company data show that since its launch, Eliquis has been prescribed to more than 15 million Americans, delivering an estimated $3 billion in healthcare cost savings and avoidance, including a decrease in hospitalizations and rehabilitation needs, for every 100,000 patients that were treated.

The prescription anticoagulant used to decrease the risk of stroke and blood clots in adults with atrial fibrillation (AFib) not caused by a heart valve problem. It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), along with helping to prevent these conditions from recurring after the initial treatment. Further, it’s commonly used after hip or knee replacement surgery to lower the risk of blood clots forming in the legs or lungs during recovery.

Beyond adult care, the drug is approved for pediatric use in children from birth and older. In this group, it treats venous thromboembolism (VTE), considered blood clots in the legs or lungs, after at least five days of initial anticoagulant therapy, while helping to lower the risk of clots coming back.

“The BMS-Pfizer Alliance is committed to increasing patient access and affordability, which is why we are launching this direct-to-patient offering for Eliquis. Eliquis is the nation’s number one prescribed oral anticoagulant that provides important benefits to patients and the healthcare system,” Boerner added. “This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care.”

References

1. Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib). Bristol Myers Squibb. September 25, 2025. Accessed September 25, 2025. https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Builds-on-Eliquis-apixaban-Direct-to-Patient-Program-Announces-New-BMS-Patient-Connect-Platform-Offering-Sotyktu-deucravacitinib/default.aspx

2. Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis (apixaban) Option. Bristol Myers Squibb. July 17, 2025. Accessed September 25, 2025. https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-and-Pfizer-Announce-Direct-to-Patient-Eliquis-apixaban-Option/default.aspx

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Subscribe Now!